Sociedad Americana de Hirudoterapia

Continuous postoperative monitoring of cutaneous free flaps using near infrared spectroscopy.

Research article published in Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2007)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosRepez et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2007

Abstract

UNLABELLED: Reliable detection of circulatory compromise threatening free-flap viability is essential for prompt surgical intervention and flap salvage. Numerous techniques have been developed to address the issue of postoperative flap monitoring but none have achieved universal acceptance. Near infrared spectroscopy (NIRS) is a noninvasive technique that allows continuous monitoring of tissue oxygenation and perfusion. It is increasingly recognised to be a reliable method for flap viability assessment. This study was designed to investigate the ability of NIRS to detect and identify microvascular thrombosis endangering flap survival. To our knowledge, this is the first clinical evaluation of NIRS used for continuous monitoring of free flaps. METHODS: Fifty flaps used for autologous breast reconstruction in 48 patients were included in this prospective clinical study. NIRS was employed for 72-h continuous postoperative monitoring. The data were compared to findings of clinical assessments. RESULTS: Ten flaps (20%) developed 13 anastomosis thromboses (two arterial and 11 venous). NIRS detected all cases of flow failure prior to clinical observation with no false positives or negatives. Based on consistent patterns of NIRS parameter changes, it was possible to differentiate between changes caused by arterial and venous thrombosis with accuracy before surgical re-exploration. The salvage rate was 70%. Overall flap viability was 94%. CONCLUSIONS: Continuous NIRS monitoring can reliably detect and identify early stages of arterial and venous thrombosis, and is a credible method for noninvasive postoperative flap surveillance. Based on these findings, we advocate its use for monitoring of flaps with a cutaneous component.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEvaluation StudyJournal Article
Indexed MeSH termsAdultFemaleGraft RejectionGraft SurvivalHumansMammaplastyMiddle AgedPostoperative CarePostoperative ComplicationsProspective StudiesSpectroscopy, Near-InfraredSurgical Flaps

Resumen

Reliable detection of circulatory compromise threatening free-flap viability is essential for prompt surgical intervention and flap salvage. Numerous techniques have been developed to address the issue of postoperative flap monitoring but none have achieved universal acceptance.

Por qué esto importa para la hirudoterapia

This prospective clinical study evaluated near-infrared spectroscopy (NIRS) for continuous postoperative monitoring of 50 free flaps used for autologous breast reconstruction in 48 patients over 72 hours. NIRS detected all 13 anastomosis thromboses (2 arterial, 11 venous) before clinical observation with no false positives or negatives, achieving a 70% salvage rate and 94% overall flap viability. The abstract concludes that continuous NIRS monitoring reliably detects early arterial and venous thrombosis and advocates its use for monitoring flaps with a cutaneous component. The abstract contains no mention of leeches, hirudotherapy, or any leech-related content. There is no defensible leech link from this abstract.

Citación

Continuous postoperative monitoring of cutaneous free flaps using near infrared spectroscopy.

Repez et al. · Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2007

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.